Anti-VEGF_e

Faculty

Alan Berger, MD
Michael Dollin, MD
Phil Hooper, MD
Peter Kertes, MD
Wai-Ching Lam, MD

Scientific Planning Committee

Varun Chaudhary (Chair), MD
Bernard R. Hurley, MD
Walter T. Delpero, MD

Objectives

At the end of this session, participants will be able to:

Integrate the findings from the latest anti-VEGF therapeutic trials into clinical practice
Understand when anti-VEGF therapy should be used over other therapeutic options such as laser or observation
Describe how OCT-A can enhance therapeutic decision-making
Assess the clinical and patient factors that may suggest anti-VEGF therapy has become futile

Schedule

0630	Welcome and introductions · Varun Chaudhary
0635	Protocol T – What’s best for your patient? · Wai-Ching Lam
0650	Approaches to anti-VEGF therapy – How and when? · Peter Kertes
0705	Role of OCT-A in guiding therapeutic decisions · Alan Berger
0720	When to throw in the towel · Phil Hooper
0735	Case-based panel discussion · Michael Dollin and faculty
0800	Adjourn

Breakfast will be served.

This symposium was co-developed by the Canadian Ophthalmological Society and Bayer and was planned to achieve scientific integrity, objectivity and balance.